SCHEMBL5118711

SCHEMBL5118711

Cc1cc(C)c2oc(=O)c(-c3cc4c(=O)oc5c(C)cc(C)cc5c4o3)c(O)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 13/20 0.47
CSNK2B P67870 13/20 0.47
CSNK2A1 P68400 13/20 0.47
ESR1 P03372 4/20 0.43
ESR2 Q92731 4/20 0.43
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
ATM Q13315 2/20 0.34
MAOB P27338 1/20 0.34
KDM4E B2RXH2 1/20 0.34
PLK4 O00444 1/20 0.34
IKBKB O14920 1/20 0.34
AURKA O14965 1/20 0.34
CA12 O43570 1/20 0.34
NUAK1 O60285 1/20 0.34
USP2 O75604 1/20 0.34
GSR P00390 1/20 0.34
EGFR P00533 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5730945 0.89 ESR1 (0.46) CSNK2A2CSNK2BCSNK2A1ESR1ESR2
SCHEMBL5120320 0.80 ESR2 (0.43) CSNK2A2CSNK2BCSNK2A1ESR2MEN1
SCHEMBL5115083 0.77 NQO1 (0.55) CSNK2A2CSNK2BCSNK2A1ESR1ESR2
SCHEMBL5125176 0.77 MAOB (0.56) CSNK2A2CSNK2BCSNK2A1MEN1KMT2A
SCHEMBL5124524 0.76 CSNK2A2 (0.43) CSNK2A2CSNK2BCSNK2A1MEN1KMT2A
SCHEMBL5118825 0.76 NQO1 (0.52) CSNK2A2CSNK2BCSNK2A1ESR1ESR2
SCHEMBL5119584 0.76 ESR1 (0.45) CSNK2A2CSNK2BCSNK2A1ESR1ESR2
SCHEMBL5115329 0.74 MAOB (0.44) CSNK2A2CSNK2BCSNK2A1ESR1ESR2
SCHEMBL5117787 0.72 ESR2 (0.40) CSNK2A2CSNK2BCSNK2A1ESR1ESR2
SCHEMBL5119551 0.72 NQO1 (0.42) CSNK2A2CSNK2BCSNK2A1ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US claimed
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US claimed
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action CYP11B2, CYP11B1, LTC4S CSNK2A2 886/4885CSNK2B 767/4885CSNK2A1 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.